Related Experiment Video
Updated: Jul 26, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Optimizing adjuvant treatment strategy in advanced clear cell endometrial cancer: systematic review and meta-analysis
Osnat Elyashiv1, Simran Vaja2, Melin Dokmeci3
1University College London, Cancer Research UK & University College London Cancer Trials Centre, London, UK; Edith Wolfson Medical Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Holon, Israel.
Objective:
Clear cell endometrial cancer is a rare, aggressive sub-type with a poor prognosis. Due to its low incidence, treatment strategies are often extrapolated from other high-risk histologies. Optimal adjuvant treatment following primary surgery for advanced clear cell endometrial cancer is unclear. This meta-analysis compares radiotherapy-containing strategies with chemotherapy alone in the adjuvant setting.
Methods:
We conducted a systematic literature review (Medline, Cochrane CENTRAL, Embase, and Web of Science) of studies evaluating first-line adjuvant treatment for advanced clear cell endometrial cancer. Inclusion criteria were: English language; full peer-reviewed manuscript; International Federation of Gynecology and Obstetrics 2009 stage III/IV clear cell patients receiving adjuvant chemotherapy and/or radiotherapy after primary surgery (staging or cytoreductive); and overall survival data specific to this cohort. Studies reporting overall survival estimates comparing treatment groups in advanced clear cell endometrial cancer patients were included. A random-effects model was used to estimate the overall survival hazard ratio (HR) and 95% confidence interval (CI), pooled using the generic inverse-variance method with adjusted weights.
Results:
The search yielded 5421 results, of which 6 met the inclusion criteria. 1 article included 2 independent cohorts, resulting in 7 studies included in the meta-analysis. A total of 1266 patients received adjuvant chemotherapy alone, and 531 patients received adjuvant chemoradiotherapy or radiotherapy only. The pooled HR from 7 studies was 0.63 (95% CI 0.53 to 0.74), corresponding to a 37% reduction in the risk of death for patients receiving adjuvant chemoradiotherapy or radiotherapy compared with chemotherapy alone. The results were consistent across the studies, with no evidence of heterogeneity (p =.89).
Conclusions:
Adjuvant chemoradiotherapy or radiotherapy was associated with improved overall survival in advanced clear cell endometrial cancer compared with chemotherapy alone. These findings support prospective validation and define the optimal integration of radiotherapy in this setting.
